By Counterforce Health Team in Voydeya (danicopan) —

Myths vs. Facts: Getting Voydeya (danicopan) Covered by Aetna (CVS Health) in New York

Answer Box: Getting Voydeya (danicopan) Covered by Aetna (CVS Health) in New York

Voydeya (danicopan) requires prior authorization from Aetna CVS Health for PNH patients with extravascular hemolysis. Key requirements include confirmed PNH diagnosis by flow cytometry, current C5 inhibitor therapy, documented EVH evidence (labs showing persistent anemia/hemolysis), REMS enrollment, and up-to-date vaccinations. Submit via Availity portal or call 1-888-632-3862. Standard decisions take 72 hours; expedited reviews 24 hours. If denied, New York patients can appeal internally then request external review through the NY Department of Financial Services within 4 months.

Table of Contents

  1. Why Myths Persist About Rare Disease Coverage
  2. Top Myths vs. Facts About Voydeya Coverage
  3. What Actually Influences Aetna Approval
  4. Avoid These 5 Preventable Mistakes
  5. Quick Action Plan: 3 Steps to Take Today
  6. New York Appeal Rights
  7. Resources and Support

Why Myths Persist About Rare Disease Coverage

Misinformation about getting specialty drugs like Voydeya (danicopan) covered spreads quickly among patients and even some healthcare providers. The complexity of prior authorization requirements, REMS programs, and insurance appeals creates confusion that can delay life-changing treatment for people with paroxysmal nocturnal hemoglobinuria (PNH).

These myths often stem from outdated information, confusion between different insurers' policies, or misunderstanding how rare disease drugs are evaluated. For a medication that costs approximately $50,000-$100,000 annually and requires add-on therapy to existing C5 inhibitors, accurate information about Aetna CVS Health's specific requirements can mean the difference between quick approval and months of delays.

Counterforce Health helps patients navigate these complex approval processes by turning insurance denials into targeted, evidence-backed appeals. The platform identifies denial reasons and drafts point-by-point rebuttals aligned to each plan's specific rules, pulling the right clinical evidence to support rare disease drug approvals.

Top Myths vs. Facts About Voydeya Coverage

Myth 1: "If my hematologist prescribes Voydeya, Aetna has to cover it"

Fact: Even specialist prescriptions require prior authorization and must meet specific medical necessity criteria. Aetna CVS Health requires documented evidence of extravascular hemolysis despite optimized C5 inhibitor therapy, plus REMS compliance and vaccination requirements. Simply having a PNH diagnosis isn't enough—you need proof that standard C5 inhibitor therapy alone is insufficient.

Myth 2: "Voydeya denials can't be overturned because it's too expensive"

Fact: Cost alone cannot be the basis for denial if medical necessity criteria are met. In New York, external appeals have strong patient protections—the Department of Financial Services assigns independent medical experts who review cases based on clinical evidence, not cost. Many rare disease drug denials are overturned when proper documentation is provided.

Myth 3: "I have to try every other PNH drug first before getting Voydeya"

Fact: Voydeya is specifically approved as add-on therapy to C5 inhibitors (eculizumab or ravulizumab), not as step therapy after multiple drug failures. According to Aetna's prior authorization criteria, you need to demonstrate inadequate response to C5 inhibitor therapy, not failure of all available treatments.

Myth 4: "The REMS program means I can't get insurance coverage"

Fact: REMS (Risk Evaluation and Mitigation Strategy) requirements are safety protocols, not coverage barriers. While prescribers must complete REMS certification and ensure proper vaccinations, these are standard safety measures that don't prevent insurance approval. CVS Specialty Pharmacy is REMS-certified and can coordinate with your Aetna coverage once prior authorization is approved.

Myth 5: "Appeals take forever and never work"

Fact: In New York, internal appeals must be decided within specific timeframes—typically 30 days for standard reviews, 72 hours for expedited cases. External appeals through NY DFS are decided within 30 days (72 hours for expedited). New York's 2025 healthcare appeals reforms have streamlined the process and increased overturn rates.

Myth 6: "I need to be hospitalized to get urgent approval"

Fact: Expedited reviews are available for situations where delays could seriously jeopardize health, including severe anemia requiring transfusions or hemolytic crises. You don't need to be hospitalized—documentation from your hematologist about the urgency is sufficient for a 24-hour expedited prior authorization decision.

Myth 7: "Generic alternatives are always required first"

Fact: There are no generic versions of Voydeya (danicopan) or equivalent Factor D inhibitors. While Aetna may require documentation of C5 inhibitor use, there's no requirement to try generic alternatives because none exist for this specific mechanism of action.

Myth 8: "Out-of-network specialists can't help with appeals"

Fact: While in-network specialists may streamline the process, expert opinions from out-of-network PNH specialists can strengthen appeals, especially for complex cases. The clinical evidence and specialist expertise matter more than network status when building a strong appeal case.

What Actually Influences Aetna Approval

Medical Necessity Documentation

Aetna CVS Health evaluates Voydeya requests based on specific clinical criteria outlined in their Clinical Policy Bulletins:

  • Confirmed PNH diagnosis via high-sensitivity flow cytometry showing GPI-deficient clones
  • Current C5 inhibitor therapy (eculizumab or ravulizumab) with documented dosing and duration
  • Evidence of extravascular hemolysis despite optimized C5 therapy:
    • Persistent anemia (hemoglobin levels)
    • Elevated reticulocyte counts
    • Ongoing transfusion requirements
    • LDH trends showing inadequate hemolysis control

REMS Compliance

The Voydeya REMS program requires:

  • Prescriber enrollment and certification
  • Patient counseling on infection risks
  • Up-to-date vaccinations against encapsulated bacteria (meningococcal, pneumococcal, Haemophilus influenzae type b)
  • Vaccination completion ≥2 weeks before starting Voydeya (or antibacterial prophylaxis if urgent)

Submission Quality

Complete prior authorization requests include:

  • Hematology consultation notes with treatment history
  • Laboratory results showing EVH evidence
  • Vaccination records with dates and types
  • REMS enrollment documentation
  • Clear clinical narrative explaining why Voydeya is medically necessary

Avoid These 5 Preventable Mistakes

1. Incomplete Vaccination Documentation

The mistake: Submitting requests without complete vaccination records or assuming adult vaccines aren't necessary.

The fix: Obtain detailed immunization records showing meningococcal and pneumococcal vaccines are current per ACIP guidelines. If vaccines need updating, complete them ≥2 weeks before the PA submission or document urgent clinical need with prophylactic antibiotic plans.

2. Missing EVH Evidence

The mistake: Assuming PNH diagnosis alone justifies Voydeya, without proving inadequate response to C5 inhibitors.

The fix: Compile laboratory trends showing persistent anemia, elevated reticulocytes, or ongoing transfusion needs despite optimized C5 inhibitor therapy. Include specific hemoglobin levels, LDH values, and transfusion dates.

3. Wrong Submission Channel

The mistake: Submitting paper forms when electronic submission is faster, or using incorrect contact information.

The fix: Use Availity portal for fastest processing. For phone submissions, call 1-888-632-3862 for commercial plans or 1-800-624-0756 for Medicare Advantage.

4. Inadequate Clinical Narrative

The mistake: Generic prior authorization forms without specific details about why Voydeya is necessary for this patient.

The fix: Include a detailed hematologist letter explaining the patient's specific clinical situation, why C5 inhibitor monotherapy is insufficient, and how Voydeya addresses uncontrolled extravascular hemolysis.

5. Not Requesting Expedited Review When Appropriate

The mistake: Accepting standard 72-hour timelines when the patient's condition warrants urgent review.

The fix: Request expedited review (24-hour decision) when severe anemia, recent hospitalizations, or frequent transfusions demonstrate that delays could seriously jeopardize health.

Quick Action Plan: 3 Steps to Take Today

Step 1: Gather Required Documentation (Today)

Contact your hematologist's office to compile:

  • Flow cytometry report confirming PNH diagnosis
  • Current C5 inhibitor prescription and infusion records
  • Recent lab results (hemoglobin, LDH, reticulocyte count)
  • Vaccination records from your primary care provider
  • Transfusion history and frequency

Step 2: Verify REMS and Coverage Requirements (This Week)

  • Confirm your hematologist is enrolled in the Voydeya REMS program
  • Update any missing vaccinations (allow ≥2 weeks before starting Voydeya)
  • Verify CVS Specialty Pharmacy is in-network for your Aetna plan
  • Check if your plan requires specialty pharmacy dispensing

Step 3: Submit Complete Prior Authorization (Within 2 Weeks)

Submit via Availity portal or call 1-888-632-3862 with:

  • Completed PA form with all clinical documentation
  • Hematologist letter explaining medical necessity
  • REMS compliance documentation
  • Request expedited review if clinically urgent
From our advocates: We've seen Voydeya approvals expedited from weeks to days when patients proactively gathered vaccination records and lab trends before their hematologist submitted the PA. Having everything ready upfront prevents the back-and-forth requests for additional information that commonly delay specialty drug approvals.

New York Appeal Rights

If Aetna denies your Voydeya request, New York offers strong patient protections through a two-level appeal process.

Internal Appeals

First, file an internal appeal with Aetna:

  • Timeline: 180 days from denial notice to file
  • Decision timeframe: 30 days (72 hours for expedited)
  • How to file: Call member services number on your ID card or submit via Aetna member portal

External Review Through NY DFS

After internal appeal denial, request external review:

  • Timeline: 4 months from final adverse determination
  • Decision timeframe: 30 days standard, 72 hours expedited
  • How to file: NY Department of Financial Services portal
  • Cost: Maximum $25 fee (waived for financial hardship)

New York's 2025 reforms include automatic forwarding of medical necessity denials to external review unless you opt out, and binding decisions with $50,000 penalties for insurer non-compliance.

For free assistance, contact Community Health Advocates at 888-614-5400.

Resources and Support

Official Coverage and Appeals

Clinical and Safety Resources

Patient Assistance

  • Community Health Advocates: 888-614-5400
  • Counterforce Health - Insurance appeals platform
  • NY Healthcare Appeals Ombudsman: 1-800-NYS-APPEAL

Emergency Contacts

  • Aetna Commercial PA: 1-888-632-3862
  • Aetna Medicare Advantage: 1-800-624-0756
  • Expedited appeals: Same numbers, request urgent review

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare providers and insurance plan for specific guidance regarding your situation. For official appeals assistance in New York, contact the Department of Financial Services or Community Health Advocates.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.